anti pdgfc  (Proteintech)

Journal: Cell Death Discovery

Article Title: NRG1/PDGFC loop between fibroblasts and cancer cells drives paclitaxel resistance via ferroptosis suppression in breast cancer

doi: 10.1038/s41420-025-02785-2

Figure Lengend Snippet: A Western blot analysis of the effects of CM from normal breast epithelial cells and BC cells on FAP expression, as well as NRG1 secretion and expression in fibroblasts ( n = 3). B Comparison of PDGFC expression levels in BC cells and normal breast epithelial cells using Western blot and Coomassie Brilliant Blue (Cbb) staining ( n = 3). C ELISA analysis of PDGFC content in the CM of BC cells versus normal breast epithelial cells ( n = 3). D ENCORI database analysis of the correlation between NRG1 and PDGFC in BC tissues. E Western blot analysis of FAP expression, and NRG1 expression and secretion in fibroblasts after the addition of exogenous PDGFC ( n = 3). F Western blot evaluation of the inhibitory effect of PDGFRα inhibitors on NRG1 expression and secretion in fibroblasts ( n = 3). G Western blot analysis of the effects of exogenous NRG1 and AKT inhibitors on PDGFC expression in BC cells ( n = 3). H ELISA analysis of changes in PDGFC content in the CM of BC cells ( n = 3). Data are expressed as the mean ± S.D. for all panels: # P < 0.05, ** P < 0.01, ***, ### P < 0.001.

Article Snippet: PDGFC Polyclonal antibody , 1:1000 , 55076-1-AP, Proteintech.

Techniques: Western Blot, Expressing, Comparison, Staining, Enzyme-linked Immunosorbent Assay

Journal: Cell Death Discovery

Article Title: NRG1/PDGFC loop between fibroblasts and cancer cells drives paclitaxel resistance via ferroptosis suppression in breast cancer

doi: 10.1038/s41420-025-02785-2

Figure Lengend Snippet: A Schematic diagram of the mouse BC xenograft model established using MDA-MB-231 cells. PTX (15 mg/kg, intraperitoneally, every three days) and recombinant NRG1 protein (5 μg/kg, intratumorally, twice a week) were administered starting on day 11 post-tumor implantation. B Representative images of excised tumors from the mice ( n = 6). C Tumor volumes were measured every five days, and mice were sacrificed on day 30 for analysis ( n = 6). D Quantification of the excised tumor weights ( n = 6). E MDA-MB-231 cells and HFL1 cells were co-injected at a 1:1 ratio into the subcutaneous tissue of nude mice to establish a BC model. PTX (15 mg/kg, intraperitoneally, every three days) and recombinant PDGFC protein (5 μg/kg, intratumorally, twice a week) were administered starting on day 16 post-tumor implantation. F Representative images of excised tumors ( n = 6). G Quantification of tumor volume changes in mice ( n = 6). H Quantification of excised tumor weights ( n = 6). Data are expressed as the mean ± S.D. for all panels: ## P < 0.01, *** , ### P < 0.001.

Article Snippet: PDGFC Polyclonal antibody , 1:1000 , 55076-1-AP, Proteintech.

Techniques: Recombinant, Tumor Implantation, Injection

Journal: Cell Death Discovery

Article Title: NRG1/PDGFC loop between fibroblasts and cancer cells drives paclitaxel resistance via ferroptosis suppression in breast cancer

doi: 10.1038/s41420-025-02785-2

Figure Lengend Snippet: NRG1 derived from CAFs promotes ferroptosis escape in BC cells through the activation of the AKT/mTOR signaling pathway, thereby promoting PTX resistance in BC cells. Meanwhile, activation of the AKT/mTOR signaling pathway induces high expression of PDGFC, and BC cells release PDGFC to activate fibroblasts and further release NRG1, ultimately forming the NRG1/PDGFC positive feedback loop.

Article Snippet: PDGFC Polyclonal antibody , 1:1000 , 55076-1-AP, Proteintech.

Techniques: Derivative Assay, Activation Assay, Expressing

Journal: Signal Transduction and Targeted Therapy

Article Title: C/EBPβ activation in vascular smooth muscle cells promotes hyperlipidemia-induced phenotypic transition and arterial stiffness

doi: 10.1038/s41392-025-02196-w

Figure Lengend Snippet: Downstream secretory factor regulated by C/EBPβ—PDGF-CC levels increased. a Screening for exocytosis factor genes that could be bound by C/EBPβ in VSMCs after MBD-Chol stimulation, horizontal coordinates represent fold change (log 2 ), vertical coordinates represent P value (log 10 ). b Levels of PDGF-CC in murine VSMCs supernatants, N = 3. c Levels of TNFSF11 in murine VSMCs supernatants, N = 3. d Volcano plot showed the difference in genes expression levels in human VSMCs after 10 μg/ml MBD-Chol treatment for 0 h and 72 h, blue for genes down-regulated expression, red for genes up-regulated expression, horizontal coordinates represent fold change (log 2 ), vertical coordinates represent P value (log 10 ), the threshold for P -value is 0.05, the threshold for fold change is 0.8. e C/EBPβ gene expression levels in VSMCs of human species. f PDGF-C gene expression levels in VSMCs of human species. g Protein expression levels detected by WB in murine VSMCs (representative images). h Statistical results of protein expression levels, N = 3. * p < 0.05 and *** p < 0.001

Article Snippet: Membranes were blocked with 5% non-fat milk in Tris-buffered saline with Tween-20 (TBST) at room temperature for 2 h. The membranes were then incubated overnight at 4 °C with primary antibodies against C/EBPβ (Abcam, MA, USA; ab32358), GAPDH (Abcam, ab9485), CD68 (Proteintech Group; 28058-1-AP), ACTA2 (Abcam, ab5694), LGALS3 (CST, MA, USA; #87985), PDGF-CC (Abclonal; A15174), TNFSF11 (CUSBIO; CSB-PA003937), and DAAM1 (Proteintech Group; 14876-1-AP).

Techniques: Expressing, Gene Expression

Journal: Journal of Translational Medicine

Article Title: Targeting PDGF-CC as a promising therapeutic strategy to inhibit cholangiocarcinoma progression

doi: 10.1186/s12967-024-05857-6

Figure Lengend Snippet: PDGF-CC promoted CCA aggressiveness in vitro through PDGFR-α in vitro. (A, B) MTT assays showing the proliferation of QBC939 (A) and HuCCT1 (B) cells treated with DMSO (control), IgG, anti-PDGF-CC antibody, or STI571. (C, D) Representative images (C) and quantitative analysis (D) of migration and invasion assays in QBC939 cells treated with DMSO, IgG, anti-PDGF-CC, or STI571. (E, F) Representative images (E) and quantitative analysis (F) of migration and invasion assays in HuCCT1 cells. (G, H) Representative images (G) and quantitative analysis (H) of colony formation assays for QBC939 and HuCCT1 cells, showing a significant reduction in colony numbers after treatment with anti-PDGF-CC and STI571. Scale bars: 100 μm. Statistical significance was assessed using one-way ANOVA followed by Dunnett’s post-hoc tests. Error bars represent the SD of three independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001

Article Snippet: The sections were then blocked with a 5% BSA blocking solution before being incubated overnight at 4 °C with primary antibodies against PDGF-CC (1:50, Huayun, HY-ab244114) and CK-19 (1:200, Proteintech, 14965-1-AP).

Techniques: In Vitro, Control, Migration

Journal: Journal of Translational Medicine

Article Title: Targeting PDGF-CC as a promising therapeutic strategy to inhibit cholangiocarcinoma progression

doi: 10.1186/s12967-024-05857-6

Figure Lengend Snippet: PDGF-CC promoted CCA aggressiveness in vitro through PDGFR-α in vivo. (A) Schematic representation illustrating the establishment of the xenograft model. (B) Representative images of QBC939 xenografts from nude mice treated with DMSO (2%), IgG (50 µg/kg), anti-PDGF-CC antibodies (50 µg/kg), or STI571 (50 mg/kg) ( n = 5). (C, D) Tumor volumes (C) and weights (D) of QBC939 xenografts from different treatment groups. (E) Representative images of HuCCT1 xenografts from nude mice treated with DMSO (2%), IgG (50 µg/kg), anti-PDGF-CC antibodies (50 µg/kg), or STI571 (50 mg/kg). (F, G) Tumor volumes (F) and weights (G) of HuCCT1 xenografts from different treatment groups ( n = 5). (H–J) Representative images (H) and quantitative analysis (I, J) of immunohistochemical staining for Ki67 expression in QBC939 (I) and HuCCT1 (J) xenografts. Scale bars: 100 μm. Statistical significance was determined using one-way ANOVA followed by Dunnett’s post-hoc tests. Error bars represent the standard deviation (SD) of three independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001

Article Snippet: The sections were then blocked with a 5% BSA blocking solution before being incubated overnight at 4 °C with primary antibodies against PDGF-CC (1:50, Huayun, HY-ab244114) and CK-19 (1:200, Proteintech, 14965-1-AP).

Techniques: In Vitro, In Vivo, Immunohistochemical staining, Staining, Expressing, Standard Deviation